International Scientific Workshop Focuses on New Methods for Vaccine Development

Newark, Delaware, September 10, 2007-- Leading scientists from around the world will meet in Wilmington, Delaware next week to discuss innovative approaches for producing life-saving vaccines and antibodies. More than 125 scientists and business leaders will be participating in “New Cells for New Vaccines II: Focus on Respiratory Virus Diseases” on September 17-19 at the Hotel du Pont. The international scientific workshop is being organized by the Fraunhofer USA Center for Molecular Biotechnology (CMB) and InB:Biotechnologies, Inc. of Newark, Delaware, under the auspices of the International Association for Biologicals (IABS). According to Dr. Vidadi Yusibov, Executive Director of the Fraunhofer USA Center for Molecular Biotechnology, “The past fifty years have seen an increase in the types of cells that can be used for vaccine and antibody production, however, there remains a need for new cell substrates that can provide safer, faster and more cost effective production alternatives to current techniques, especially with the potential threat of an influenza pandemic.” “A key aspect of the success and viability of a vaccine development project is the choice of an appropriate cell substrate,” said Dr. Geoffrey Schild, Chief Scientific Officer of InB:Biotechnologies and a Director of IABS. “The advantages of plant, animal and insect cell systems are increasingly being recognized and many projects are in progress internationally, including development of respiratory virus, cervical cancer, anthrax and malaria vaccines, as well as therapeutic antibodies to treat influenza infections.” New Cells for New Vaccines II: Focus on Respiratory Virus Diseases will be of interest to scientists and business leaders in the biotechnology and pharmaceutical industry involved in vaccine development and production, as well as public health officials, medical and veterinary experts. More details and registration information are available on the meeting web site (www.NewCellsforNewVaccines.com). For press registration to attend the workshop or for more information, contact: Dale Ervin, Fraunhofer USA CMB at 302-369-1708 or [email protected] About Fraunhofer USA Center for Molecular Biotechnology: Fraunhofer USA CMB, a division of Fraunhofer USA, Inc., is a not-for-profit research organization whose mission is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. CMB’s technology provides a safe, rapid and economical alternative for vaccine production. The Center conducts research in the area of plant biotechnology, utilizing new, cutting edge technologies to assist the diagnosis, prevention and treatment of human and animal diseases. The Center houses individuals with expertise and excellence in plant virology, pathology, molecular biology, immunology, vaccinology, protein engineering, and biochemistry. Fraunhofer USA, Inc. is a subsidiary of Fraunhofer Gesellschaft, Europe’s largest organization for applied research. Further information is available at www.fraunhofer-cmb.org.

Suggested Articles

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Broad Institute researchers showed that base-editing the Tmc1 gene preserved hair cells that helped transmit sound in the ears of mice.